Positive results for Eli Lilly in Alzheimer’s

Last year, Biogen, Eisai and Swedish BioArctic scored big with a positive phase III readout in Alzheimer´s disease. Now, Eli Lilly follows with a second positive phase III readout with their Alzheimer´s candidate donanemab. While adding to the competition, Eli Lilly’s latest results also further validate the amyloid beta antibody approach.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/05/positive-results-for-eli-lilly-in-alzheimers/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se